riximyo
sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastické činidlá - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. len obmedzené údaje o účinnosti a bezpečnosti pacientov v minulosti liečených monoklonálne protilátky, vrátane rituximab alebo pacientov, žiaruvzdorné na predchádzajúcu rituximab plus chemoterapia. pozri časť 5. 1 pre ďalšie informácie. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab bolo preukázané, že znižujú rýchlosť progresie poškodenia kĺbov, merané podľa x-ray a zlepšiť fyzickú funkciu, keď uvedené v kombinácii s metotrexátom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).
chlopňa srdcová biolog. sorin freedom solo
corcym s.r.l. (predtým sorin) via crescentino 13040 saluggia taliansko -
chlopňa srdcová perikardiálna solo smart
livanova canada corp. 5005 frase way british columbia kanada -
filter emboloprotektívny filterwire ez
boston scientific corporation 300 boston scientific way 01752 marlborough, ma spojené štáty americké -
glukomer clever chek td-4231 solo
taidoc technology corp. 4f, no. 88 & 90, sec. 1, kwang-fu road 241 san chung taipei county taiwan -
glukomer optium xceed solo
abbott diagnostics division abbott park chicago, illinois spojené štáty americké -
hadička viazacia resoloops sterilná
resorba medical gmbh am flachmoor 16 nürnberg nemecko -
katéter power picc solo2
bard access systems inc. 605 north 5600 west 84116 salt lake city, ut spojené štáty americké -
katéter vodiaci a / alebo pre emboloterapiu
cook ireland ltd.,irsko Írsko -
lôžko polohovacie nastaviteľné solo
invacare deutschland gmbh bad oeynhausen, nemecko -